Albany Molecular Research, Inc. Opens New Facilities in Singapore and India
News Nov 02, 2005
Albany Molecular Research, Inc., has announced that its wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte. Ltd. (AMRSRC) has moved into permanent laboratory facilities in Singapore that provide room for significant growth.
Earlier this year, the company established AMRSRC in temporary facilities while the new laboratories were under construction. New facilities are now also operational in Hyderabad, India.
In Singapore, AMRI's new 16,000 square foot facility is located in Science Park III, near the Biopolis, a major biomedical research hub. The facility can currently accommodate over 50 scientists. Capabilities there include medicinal chemistry support, custom synthesis of building blocks and scaffolds, as well as non-GMP scale up.
AMRI has an additional 29,000 square feet of space in Singapore at this facility and currently plans to add laboratories for cGMP synthesis and analytical chemistry, as well as additional facilities for chemical synthesis.
The company also announced that it has opened its first laboratory in India. Albany Molecular Research Hyderabad Research Centre, Pvt. Ltd. (AMRHRC), a wholly owned subsidiary of the company, is located in the ICICI Knowledge Park near Hyderabad.
The newly constructed laboratory holds up to 12 scientists and is being used for custom synthesis of scaffolds and building blocks, as well as preparation of reference standards.
A second laboratory for preparing up to kilogram quantities of pharmaceutical intermediates, starting materials and other compounds is currently under construction and expected to be operational by early next year. Together, the two laboratories in India are anticipated to accommodate up to 30 scientists.
"The move into our permanent home in Singapore, and the opening of our first laboratory in India mark two more milestones in AMRI's history," said Chairman, CEO and President Thomas E. D'Ambra, Ph.D.
"Our worldwide chemistry services platform has enhanced our ability to provide customers with a flexible range of services and competitive cost models. Customer response to our flexible mix of global and U.S.-based resources has been overwhelmingly positive. As we approach 2006, we look forward to further expansions in Singapore and India and the continued success of our global chemistry platform."
AMRI's Singapore operations are being led by Polivina Jolicia F. Gauuan, Ph.D., who joined the company in 1995 after completing her Ph.D. in organic chemistry at the State University of New York at Albany. She relocated to Singapore, along with three other U.S.-based scientists, to form the site management team. AMRSRC currently has nineteen employees, including fifteen scientists.
"The support and encouragement we have received from the Singapore government and the Biomedical Sciences Group of the Economic Development Board has been vital to the success of our Phase I project," added D'Ambra. "I would like to take the opportunity to thank them for their efforts and congratulate them for their vision and forward thinking. Singapore has a business supportive culture."
AMRI's operations in India are led by Rajesh Shenoy, Ph.D., who joined AMRI in 1998. Dr. Shenoy earned his Ph.D. at the University of Akron and conducted postdoctoral research at Kent State University. He relocated to India, along with two other U.S.-based scientists, to form the site management team. AMRHRC currently has ten employees, including eight scientists.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018